Pfizer’s sasanlimab in combo with BCG improves EFS in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer: New York Monday, January 13, 2025, 13:00 Hrs [IST] ...
Pfizer is expected to rebound in 2025 with growth stabilized and dividend growth to continue. Learn why PFE stock is a Buy.
Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name ...
Patients in the study with advanced bladder cancer had less risk of cancer progressing or returning when treated with ...
A 'game-changer' study found advanced bladder cancer patients treated with the drug durvalumab were a third less likely to ...
One of the two North Korean soldiers captured by Ukraine has claimed during questioning that he thought he was going for training, not to the war against Ukraine, Kyiv's security s... The former head ...
More than 66,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback